Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals.

By F. Djouad, P. Plence, C. Bony, P. Tropel, F. Apparailly, J. Sany, D. Noël, C. Jorgensen. Blood, 2003

1,235 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a22a5181fda898833056f9f16e2aaace5b6cd964

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. A. Keating
2. W. Fibbe
3. D. Prockop
4. Frank Barry
5. M. Kay
6. M. Kwa
7. C. Herberts
8. H. Hermsen

In Molecular Biology

1. W. Stetler-Stevenson
2. M. Kay
3. A. Keating
4. D. Prockop
5. J. Marshall
6. M. Kwa
7. Toren Finkel
8. C. Herberts

Citations in the corpus

• Risk factors in the development of stem cell therapy (2011, background): “The secretion of various soluble factors by MSC [84] may enhance this effect.”
• T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. (2005, background): “Suppression of alloreactivity by MSCs has been reported for human [14–17] as well as baboon [18] and mouse MSCs [ 19 ].”
• Mesenchymal stromal cells: new directions. (2012, background): “Although there is a growing body of literature in this area (Djouad et al., 2003), the outcomes of experimental models appear to be conflicting.”
• Mesenchymal stem cells: clinical applications and biological characterization. (2004, background): “postulate that a soluble factor released by splenocyte-activated MSCs is involved in the immunosuppression and suggest that CD8+ regulatory cells are involved in the inhibition of allogeneic lymphocyte proliferation by MSCs (Djouad et al., 2003).”
• Sarcoma Derived from Cultured Mesenchymal Stem Cells (2007, background): “In addition, MSCs can synergize with other cell types in cancer evolution [39] and their immunomodulatory properties [40] can create a permissive environment for tumor growth in a murine melanoma model [ 41 ].”
• Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials (2012, background): “[47] Although recent position papers have suggested low probability of malignant transformation and tumour formation with MSCs, [7] our review is the first systematic analysis of the issue.”
• Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma (2006, background): “In addition, another study suggests that through their immune suppressive eff ects, transplanted MSCs may enhance tumor growth in vivo (19).”
• Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications (2005, methodology): “Platelet concentrates have been used for clinical oral surgery applications to deliver growth factors in high concentration to sites requiring bone grafting (Camargo et al., 2002; Dugrillon et al., 2002; Tozum and Demiralp, 2003).”
• Immunomodulatory effect of human adipose tissue‐derived adult stem cells: comparison with bone marrow mesenchymal stem cells (2005, background): “Several studies reported on the in vitro and in vivo immunosuppressive properties of BM-MSCs (Bartholomew et al, 2002; Djouad et al, 2003; Le Blanc et al, 2003; Tse et al, 2003).”